National Comprehensive Cancer Network

|
|
|
|
For Patients
About the NCCN Clinical Practice Guidelines in Oncology™
Recent Updates to NCCN Clinical Practice Guidelines in Oncology™
NCCN Categories of Evidence and Consensus
NCCN Guidelines Steering Committee
Submission Request to the NCCN Guidelines Panels
NCCN Guidelines Panels-Meeting Schedule
NCCN Drugs & Biologics Compendium™
About the NCCN Drugs & Biologics Compendium™
Compendium Chapters
No Longer Recommended Uses
JNCCN – The Journal of the National Comprehensive Cancer Network
Subscribe Now
FAQ
JNCCN Task Force Supplements

Clinical Recommendations

NCCN Drug and Biologics Compendium - Panel Members

Professionals


Go back to previous page

 

 

   
 

NCCN Drugs & Biologics Compendium

NCCN Neuroendocrine Tumors Panel Members

These chapters of the NCCN Drugs & Biologics Compendium™ were developed directly from the NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors.

These guidelines were developed by the following NCCN Neuroendocrine Tumors Panel Members.

Orlo H. Clark, MD/Chair
UCSF Helen Diller Family Comprehensive Cancer Center
Neuroendocrine Tumors

Jaffer A. Ajani, MD
The University of Texas M. D. Anderson Cancer Center
Neuroendocrine Tumors

Al B. Benson, III, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Neuroendocrine Tumors

Jordan D. Berlin, MD
Vanderbilt-Ingram Cancer Center
Neuroendocrine Tumors

Lawrence S. Blaszkowsky, MD
Massachusetts General Hospital Cancer Center
Neuroendocrine Tumors

David Byrd, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Neuroendocrine Tumors

Michael A. Choti, MD, MBA
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroendocrine Tumors

Gerard M. Doherty, MD
University of Michigan Comprehensive Cancer Center
Neuroendocrine Tumors

Paul F. Engstrom, MD
Fox Chase Cancer Center
Neuroendocrine Tumors

David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroendocrine Tumors

John F. Gibbs, MD
Roswell Park Cancer Institute
Neuroendocrine Tumors

Martin J. Heslin, MD
University of Alabama at Birmingham Comprehensive Cancer Center
Neuroendocrine Tumors

Fouad Kandeel, MD
City of Hope Comprehensive Cancer Center
Neuroendocrine Tumors

Anne Kessinger, MD
UNMC Eppley Cancer Center at The Nebraska Medical Center
Neuroendocrine Tumors

Matthew H. Kulke, MD
Dana-Farber/Brigham and Women's Cancer Center
Neuroendocrine Tumors

Pamela Kunz, MD
Stanford Comprehensive Cancer Center
Neuroendocrine Tumors

Larry Kvols, MD
H. Lee Moffitt Cancer Center & Research Institute
Neuroendocrine Tumors

John A. Olson, Jr., MD, PhD
Duke Comprehensive Cancer Center
Neuroendocrine Tumors

Thomas W. Ratliff, MD
St. Jude Children's Research Hospital/University of Tennessee Cancer Institute
Neuroendocrine Tumors

Riad Salem, MD, MBA
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Neuroendocrine Tumors

Leonard Saltz, MD
Memorial Sloan-Kettering Cancer Center
Neuroendocrine Tumors

David E. Schteingart, MD
University of Michigan Comprehensive Cancer Center
Neuroendocrine Tumors

Manisha H. Shah, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute
Neuroendocrine Tumors

Stephen Shibata, MD
City of Hope Comprehensive Cancer Center
Neuroendocrine Tumors

Jonathan R. Strosberg, MD
H. Lee Moffitt Cancer Center & Research Institute
Neuroendocrine Tumors

Jean-Nicolas Vauthey, MD
The University of Texas M. D. Anderson Cancer Center
Neuroendocrine Tumors

James C. Yao, MD
The University of Texas M. D. Anderson Cancer Center
Neuroendocrine Tumors

Disclosures for the NCCN Neuroendocrine Tumors Guidelines Panel